About: It is Time To Drop Hydroxychloroquine From our COVID-19 Armamentarium

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: It is Time To Drop Hydroxychloroquine From our COVID-19 Armamentarium Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	It is Time To Drop Hydroxychloroquine From our COVID-19 Armamentarium
Creator	Kashour, Tarek Mbchb, Imad Tleyjeh,
source	Elsevier; PMC
abstract	Chloroquine (CQ) and hydroxychloroquine (HCQ) were among the first drugs repurposed for the treatment of SARS-CoV-2 infection. A few in vitro studies confirmed that both drugs exhibited dose dependent anti-SARS-CoV-2 activities. These observations and the encouraging results from early poorly conducted observational studies created a major hype about the therapeutic potential of these drugs in the treatment of COVID-19 disease. This was further catalyzed by media and political influences leading to a widespread use of these agents. Subsequent randomized trials revealed lack of efficacy of these agents in improving the outcomes of COVID-19 or in preventing infection in post-exposure prophylaxis studies. Nevertheless, many ongoing trials continue to actively recruit tens of thousands of patients to receive HCQ worldwide. In this perspective, we address the possible mechanisms behind the lack of efficacy and the increased risk of cardiac toxicity of HCQ in COVID-19 disease. For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens and the possible negative effect of HCQ on the antiviral type-I interferon response. Although it has been repeatedly claimed that HCQ has a longstanding safety track record for many decades in use, we present counterarguments for this contention due to disease-drug and drug-drug interactions. We discuss the molecular mechanisms and the cumulative epidemiological evidence of HCQ cardiac toxicity.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110198
has license	no-cc
sha1sum (hex)	452edb53e3bbabfb88490b02504b9f5e646d2dad
schema:url	https://doi.org/10.1016/j.mehy.2020.110198
resource representing a document's title	It is Time To Drop Hydroxychloroquine From our COVID-19 Armamentarium
has PubMed Central identifier	PMC7430273
schema:publication	Med Hypotheses
resource representing a document's body	covid:452edb53e3bbabfb88490b02504b9f5e646d2dad#body_text
is schema:about of	named entity 'improving' named entity 'initiation' named entity 'observational studies' named entity 'agents' named entity 'This' named entity 'studies' named entity 'post-exposure prophylaxis' named entity 'CREATED' named entity 'PATIENTS' named entity 'ADDRESS' named entity 'TREATMENT INITIATION' named entity 'SARS-COV-2' named entity 'ACTIVITIES' named entity 'INCREASED RISK' named entity 'RESPONSE' named entity 'EFFECT' named entity 'ABOUT' covid:arg/452edb53e3bbabfb88490b02504b9f5e646d2dad named entity 'influences' named entity 'disease' named entity 'confirmed' named entity 'observations' named entity 'hydroxychloroquine' named entity 'evidence' named entity 'tens' named entity 'These' named entity 'track record' named entity 'Although' named entity 'risk' named entity 'negative' named entity 'randomized trials' named entity 'efficacy' named entity 'pharmacological' named entity 'HCQ' named entity 'dose dependent' named entity 'Chloroquine' named entity 'hydroxychloroquine' named entity 'randomized trials' named entity 'antiviral' named entity 'HCQ' named entity 'infection' named entity 'post-exposure prophylaxis' named entity 'immunomodulatory' named entity 'cardiac arrhythmias' named entity 'COVID-19 disease' named entity '1.02' named entity 'arrhythmias' named entity 'TdP' named entity 'glycosylation' named entity 'HCQ' named entity 'plasma' named entity 'antiviral effect' named entity 'cardiac complications' named entity 'virus' named entity 'interleukin-6' named entity 'bradycardia' named entity 'torsades de pointes' named entity 'HCQ' named entity 'cardiac complications' named entity 'viral illnesses' named entity 'drug-induced QT prolongation' named entity 'QTc prolongation' named entity 'endosomal' named entity 'SARS-CoV-2' named entity 'viral RNA' named entity 'HCQ' named entity 'viral infection' named entity 'type I interferon' named entity 'action potential' named entity 'antiviral activity' named entity 'viral replication' named entity 'infection' named entity 'hydroxychloroquine' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'virus' named entity 'severe pneumonia' named entity 'HCQ' named entity 'HCQ' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software